FNYS
RXII

First New York Securities’s GALENA BIOPHARMA INC COM RXII Stock Holding History

First New York Securities’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-5,300
Closed -$16.2K – 669
2014
Q2 		$16.2K Buy
+5,300
New +$16.2K 0.02% 108

Other funds holding RXII

BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $2.46B AUM 57.16% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

First New York Securities's RXII Position: Q3 2014 in Review

First New York Securities sold out of GALENA BIOPHARMA INC COM (RXII) in Q3 2014, closing a stake of 5,300 shares — an estimated $16.2K sold.

First New York Securities first reported a position in RXII in Q2 2014 and held it in 1 quarter. The position peaked at $16.2K in Q2 2014. 85 funds tracked by Wall St. Rank hold RXII as of Q3 2014.

  • First New York Securities reported no remaining GALENA BIOPHARMA INC COM position as of Q3 2014 after selling out during the quarter.
  • First New York Securities sold 5,300 GALENA BIOPHARMA INC COM shares in Q3 2014, an estimated $16.2K.
  • First New York Securities first reported a position in GALENA BIOPHARMA INC COM in Q2 2014 and held it in 1 quarter.
  • First New York Securities's GALENA BIOPHARMA INC COM position peaked at $16.2K in Q2 2014.
  • 85 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q3 2014.

Based on First New York Securities's 13F filing for Q3 2014, filed 16 Oct 2014.